Corcept Advances ALS Drug After Survival Benefit in Phase II Trial

Corcept Therapeutics is preparing to move its amyotrophic lateral sclerosis (ALS) candidate dazucorilant into Phase III trials after demonstrating a significant survival benefit, despite missing its primary endpoint in a mid-stage study.

In the Phase II DAZALS trial, patients receiving 300 mg of dazucorilant showed an 87% reduction in risk of death over two years compared to placebo. This builds on earlier findings of an 84% reduction after one year. However, the study did not meet its primary endpoint, which measured functional improvement using the ALS Functional Rating Scale–Revised.

Dazucorilant, a selective cortisol modulator, was generally well tolerated, with mild to moderate abdominal pain being the most common side effect. Corcept plans to work with regulators, including the U.S. Food and Drug Administration, to initiate a pivotal Phase III study later this year.

The findings add to growing momentum in ALS research, where new therapies are increasingly targeting survival and disease progression.

04-05-2026